celecoxib + methotrexate + prednisone + tofacitinib

This is a combination regimen consisting of four pharmaceutical agents—celecoxib, methotrexate, prednisone, and tofacitinib. Each drug has a distinct mechanism of action and therapeutic role: - **Celecoxib** is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID). It reduces inflammation and pain by inhibiting prostaglandin synthesis. - **Methotrexate** is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, interfering with DNA synthesis and cell replication. It acts as an immunosuppressant in autoimmune diseases. - **Prednisone** is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects by modulating gene expression through the glucocorticoid receptor. - **Tofacitinib** is an oral small molecule Janus kinase (JAK) inhibitor that blocks intracellular signaling pathways involved in immune activation. This combination may be used for severe or refractory autoimmune conditions such as rheumatoid arthritis or certain cancers under metronomic chemotherapy protocols. The rationale for combining these agents includes targeting multiple inflammatory pathways, suppressing immune activity at different levels, reducing disease progression, controlling symptoms, and potentially overcoming resistance seen with monotherapy[6][8][9]. However, this specific four-drug combination does not have established approval as a fixed regimen; its use would be off-label or investigational.